Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
about
An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patientsClinical and virological efficacy of etravirine plus two active Nucleos(t)ide analogs in an heterogeneous HIV-infected populationRole of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional StudyNew therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data.Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.Dolutegravir: clinical efficacy and role in HIV therapy.Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection.Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.Mathematical modeling of HIV prevention measures including pre-exposure prophylaxis on HIV incidence in South Korea.Nephrotoxicity of HAARTEfficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged ≥3 to <12 Years.Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trialAntiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.Etravirine in CSF is highly protein boundEffect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.Etravirine Pharmacokinetics in HIV-Infected Pregnant Women.The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug ResistanceEtravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials.Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients.Pharmacoeconomics of darunavir.Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection.Etravirine for the treatment of HIV/AIDS.Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management.Switching to an etravirine-containing regimen due to drug intolerance in clinical practice.Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.Interventions for Neurocognitive Dysfunction.Etravirine and Rilpivirine Drug Resistance Among HIV-1 Subtype C Infected Children Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens in South India.F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-1-Infected, Treatment-Experienced Children and Adolescents in PIANO.Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis.Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients.Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results.Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study.Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected PatientsDual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study.Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra study.
P2860
Q26827791-A1DE0737-8818-4456-BE7C-0604A8AF7A20Q28538921-748103A7-8C01-40F0-8EE7-9D8AFDD72759Q28551624-DA64E7D6-60E3-425C-8BFB-EFC8B7326131Q30578338-105BD164-B610-445E-A1E5-C045DC4017D1Q33413634-0F0AB0D0-EA7F-4C9F-86BE-FEDE5E9D1CA7Q33725024-F4E9F664-049E-4074-BEA9-0C2D59CA4759Q34638302-3001CC96-71C5-47B1-887C-C5F8E9D38386Q35105844-AE55B46A-7E9A-4880-AE7D-1D0B49F7F944Q35129067-864EAB89-5D44-4642-BF8B-B00F062DAD30Q35167944-84B67EEC-BC7E-4B61-A97D-5939FCCF513CQ35542299-7E0E3CCC-0FDA-48BB-92E9-8635622A35FAQ35979557-E317A3F8-E2D2-4A82-AA24-F8050F87FC4DQ36179320-BCDE140B-C0E3-4F00-B6FB-4FDA459B0B5CQ36276790-ED844C3A-4F09-4DCD-8FC4-F8F098B63601Q36762988-BD627AA4-10E7-4C48-9CB9-63A0FAAB1DA6Q36969977-7647C1D8-59F2-4580-BBA8-8D8830342987Q37150339-526DA7CD-8A08-4E3E-B909-42DC2B46B5B5Q37288671-E77E3232-280D-45A7-96AF-7617D13CD13FQ37639881-0E48BBC0-F4D5-4181-81CF-CBF2B0058952Q37845854-DA676AB4-41F7-4E33-8F82-D9EA771EF513Q37847151-697610CF-D12A-46D4-9144-15970FE7B5F9Q37950517-16D76021-AEB4-44A3-9FEE-02271AAC51E4Q38003399-FBACF9CF-3A71-41B0-AEA7-91A39BBD18B8Q38096459-302814CC-005E-4B6D-97FA-5DD27FA90609Q38111430-88808583-48E8-4EA0-BCFD-4B8345739502Q38392172-6F525FB8-F1C5-414F-B75E-6FAF605FAB70Q38662696-0068232B-1F92-43B0-89E7-20941BDFD435Q38767396-4A331F26-04BB-4272-8581-1F5F7757AD50Q38792785-2690BB97-1A13-4C66-9A01-9787C693255EQ39692280-3DDE4959-8C25-4C45-AED3-2B3765960261Q39759988-F44B30A5-1D60-4FD5-BB7E-5B137DFE3CC7Q40722214-3244916B-5073-4AB6-AD11-08FF75188537Q40784890-2B1182B9-453B-4945-9C31-B641007EA9E9Q40836288-F709DC49-62AE-423B-93FD-96FA178BB4BEQ41059063-49C4DF9B-E7F8-4549-B320-9A220D43BFD3Q41217657-A7ED6EF2-F9C1-49C3-82C8-A8F3C11066B0Q41230514-5D4CF3B9-C911-42A6-8437-9F210437AFD6Q41494718-804A0891-5C6D-4D55-8C64-D61D22864AD2Q42244133-0F133F70-47FD-49DA-BA82-DB4309807774Q42287383-1FBB9AC5-E756-4CEB-8A30-57F14BA87D1E
P2860
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Efficacy and safety of etravir ...... the DUET-1 and DUET-2 trials.
@en
Efficacy and safety of etravir ...... the DUET-1 and DUET-2 trials.
@nl
type
label
Efficacy and safety of etravir ...... the DUET-1 and DUET-2 trials.
@en
Efficacy and safety of etravir ...... the DUET-1 and DUET-2 trials.
@nl
prefLabel
Efficacy and safety of etravir ...... the DUET-1 and DUET-2 trials.
@en
Efficacy and safety of etravir ...... the DUET-1 and DUET-2 trials.
@nl
P2093
P50
P356
P1433
P1476
Efficacy and safety of etravir ...... the DUET-1 and DUET-2 trials.
@en
P2093
Benoit Trottier
Brian Woodfall
James Witek
Jean-Michel Molina
Johan Vingerhoets
Richard Haubrich
Steven Nijs
William Towner
P304
P356
10.3851/IMP1662
P577
2010-01-01T00:00:00Z